Barclays Reports Dun & Bradstreet (DNB) Upgrade and $125.0 Target; Revance Therapeutics (RVNC)’s Sentiment Is 1.96

November 15, 2017 - By Peter Erickson

Among 6 analysts covering Dun & Bradstreet (NYSE:DNB), 1 have Buy rating, 0 Sell and 5 Hold. Therefore 17% are positive. Dun & Bradstreet has $130.0 highest and $105 lowest target. $117.40’s average target is 1.05% above currents $116.18 stock price. Dun & Bradstreet had 10 analyst reports since November 4, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Friday, November 3 by Robert W. Baird. The firm earned “Neutral” rating on Friday, January 20 by Goldman Sachs. The firm has “Equal-Weight” rating by Barclays Capital given on Monday, November 13. The firm has “Buy” rating given on Monday, October 23 by Robert W. Baird. Piper Jaffray maintained the stock with “Hold” rating in Wednesday, August 2 report. The stock of Dun & Bradstreet Corp (NYSE:DNB) has “Hold” rating given on Tuesday, July 25 by Stifel Nicolaus. The firm has “Underweight” rating given on Friday, February 10 by Barclays Capital.

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The company has market cap of $784.19 million. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. It currently has negative earnings. The Company’s peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection , or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Essex Woodlands Health Ventures Inc. holds 21.92% of its portfolio in Revance Therapeutics Inc for 4.59 million shares. Rhenman & Partners Asset Management Ab owns 220,000 shares or 0.83% of their US portfolio. Moreover, Arrowmark Colorado Holdings Llc has 0.67% invested in the company for 2.05 million shares. The New York-based Ghost Tree Capital Llc has invested 0.49% in the stock. Essex Investment Management Co Llc, a Massachusetts-based fund reported 124,932 shares.

Analysts await Revance Therapeutics Inc (NASDAQ:RVNC) to report earnings on February, 26. They expect $-0.95 earnings per share, 0.00% or $0.00 from last year’s $-0.95 per share. After $-1.01 actual earnings per share reported by Revance Therapeutics Inc for the previous quarter, Wall Street now forecasts -5.94% EPS growth.

It closed at $25.35 lastly. It is down 20.40% since November 15, 2016 and is uptrending. It has outperformed by 3.70% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 2 selling transactions for $685,462 activity.

It closed at $116.18 lastly. It is down 12.51% since November 15, 2016 and is downtrending. It has underperformed by 29.21% the S&P500.

Analysts await Dun & Bradstreet Corp (NYSE:DNB) to report earnings on February, 14. They expect $3.04 earnings per share, up 1.67% or $0.05 from last year’s $2.99 per share. DNB’s profit will be $112.25M for 9.55 P/E if the $3.04 EPS becomes a reality. After $1.79 actual earnings per share reported by Dun & Bradstreet Corp for the previous quarter, Wall Street now forecasts 69.83% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com